While cancer testis antigens are promising therapeutic targets, in two phase III trials for non-small cell lung cancer (NSCLC) and melanoma, MAGE-A3 (fusion protein administered with immunostimulant AS15) failed to extend disease-free survival [48]. The gene discussed is MAGEA3; the disease is non-small cell lung carcinoma.